Details of the Drug

General Information of Drug (ID: DMPGUCF)

Drug Name

Dopamine

Synonyms

Dopamin; Dopamina; Dopaminum; Dophamine; Hydroxytyramin; Hydroxytyramine; Intropin; LDP; Oxytyramine; Revimine; ASL 279; IP 498; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine [INN:BAN]; Dopaminum [INN-Latin]; L-DOPAMINE; M-Hydroxytyramine hydrochloride; Medopa (TN); Intropin [*hydrochloride*]; KW-3-060; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamine (USAN)(*hydrochloride*); A-(3,4-Dihydroxyphenyl)-b-aminoethane; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; (3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol

Indication

Disease Entry	ICD 11	Status	REF
Acromegaly	5A60.0	Approved	[1]
Carcinoid syndrome	5B10	Approved	[1]
Parkinson disease	8A00.0	Approved	[2]
Parkinsonian disorder	N.A.	Approved	[1]
Postencephalitic Parkinson disease	N.A.	Approved	[1]
Hypotension	BA20-BA21	Phase 1	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Cardiotonic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

153.18

Logarithm of the Partition Coefficient (xlogp)

-1

Rotatable Bond Count (rotbonds)

2

Hydrogen Bond Donor Count (hbonddonor)

3

Hydrogen Bond Acceptor Count (hbondacc)

3

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 65.9 mL/min/kg [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 minutes [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 470 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.87% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.74 L/kg [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Intervertebral disc protrusion	rs9378688	GMDS	OTWV79YD	[6]
Intervertebral disc protrusion	rs163030	WDR41	OTT6Q0CZ	[6]
Mental impairment disorders	Not Available	GFAP	OTQ01ZAS	[7]
-----------

Chemical Identifiers

Formula: C8H11NO2
IUPAC Name: 4-(2-aminoethyl)benzene-1,2-diol
Canonical SMILES: C1=CC(=C(C=C1CCN)O)O
InChI: InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2
InChIKey: VYFYYTLLBUKUHU-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 681
ChEBI ID: CHEBI:18243
CAS Number: 51-61-6
DrugBank ID: DB00988
TTD ID: D0T7OW
VARIDT ID: DR00283
INTEDE ID: DR0532
ACDINA ID: D00212

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Synaptic vesicle glycoprotein 2C (SLC22B3)	DT7A9GF	SV2C_HUMAN	Substrate	[9]
Vesicular amine transporter 2 (SLC18A2)	DTT7VPB	VMAT2_HUMAN	Substrate	[10]
Vesicular amine transporter 1 (SLC18A1)	DTM953D	VMAT1_HUMAN	Substrate	[10]
Sodium-dependent dopamine transporter (SLC6A3)	DT3BA8L	SC6A3_HUMAN	Substrate	[11]
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[12]
Organic cation transporter 2 (SLC22A2)	DT9IDPW	S22A2_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[14]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[14]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[14]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[15]
Catechol O-methyltransferase (COMT)	DEV3T4A	COMT_HUMAN	Substrate	[16]
Sulfotransferase 1B1 (SULT1B1)	DED5UR3	ST1B1_HUMAN	Substrate	[17]
Monoamine oxidase type B (MAO-B)	DET2NXO	AOFB_HUMAN	Substrate	[18]
Dopamine dehydroxylase (dadH)	DEL0D64	DADH_EGGLN	Substrate	[19]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5'-3' exonuclease PLD3 (PLD3)	OTL07SP2	PLD3_HUMAN	Gene/Protein Processing	[20]
Actin, cytoplasmic 1 (ACTB)	OT1MCP2F	ACTB_HUMAN	Gene/Protein Processing	[20]
ADP/ATP translocase 2 (SLC25A5)	OT1XIBMN	ADT2_HUMAN	Gene/Protein Processing	[20]
ADP/ATP translocase 3 (SLC25A6)	OT9KAJP7	ADT3_HUMAN	Gene/Protein Processing	[20]
Alpha-synuclein (SNCA)	OTPWC1MR	SYUA_HUMAN	Drug Response	[21]
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Biotransformations	[22]
Amine oxidase B (MAOB)	OTTDFM1O	AOFB_HUMAN	Biotransformations	[22]
Annexin A3 (ANXA3)	OTDD8OI7	ANXA3_HUMAN	Gene/Protein Processing	[20]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[23]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[24]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Acromegaly

ICD Disease Classification

5A60.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Vesicular amine transporter 2 (SLC18A2)	DTP	VMAT2	2.69E-02	-4.44E-02	-1.12E-01
Organic cation transporter 1 (SLC22A1)	DTP	SLC22A1	8.54E-01	1.24E-02	7.20E-02
Vesicular amine transporter 1 (SLC18A1)	DTP	VMAT1	2.65E-02	-4.30E-02	-2.34E-01
Organic cation transporter 2 (SLC22A2)	DTP	SLC22A2	8.22E-01	-1.05E-02	-3.83E-02
Synaptic vesicle glycoprotein 2C (SLC22B3)	DTP	SV2C	9.35E-01	-5.10E-02	-6.99E-02
Sodium-dependent dopamine transporter (SLC6A3)	DTP	DAT1	2.11E-01	1.59E-02	5.57E-02
Catechol O-methyltransferase (COMT)	DME	COMT	5.00E-03	9.63E-02	4.48E-01
Monoamine oxidase type B (MAO-B)	DME	MAOB	2.65E-02	1.12E-02	6.68E-02
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.36E-01	1.62E-02	1.08E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	2.40E-01	-3.31E-02	-1.97E-01
Sulfotransferase 1B1 (SULT1B1)	DME	SULT1B1	1.61E-01	2.35E-03	1.15E-02
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dopamine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Safinamide	DM0YWJC	Moderate	Decreased metabolism of Dopamine caused by Safinamide mediated inhibition of non-CYP450 enzyme.	Parkinsonism [8A00]	[25]
Opicapone	DM1BKA6	Moderate	Decreased metabolism of Dopamine caused by Opicapone mediated inhibition of non-CYP450 enzyme.	Parkinsonism [8A00]	[26]
Rasagiline	DM3WKQ4	Moderate	Additive hypertensive effects by the combination of Dopamine and Rasagiline.	Parkinsonism [8A00]	[27]
-----------

Coadministration of a Drug Treating the Disease Different from Dopamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive hypertensive effects by the combination of Dopamine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[27]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Dopamine and Droxidopa.	Autonomic nervous system disorder [8D87]	[28]
Levomilnacipran	DMV26S8	Moderate	Increased risk of rapid heart rate by the combination of Dopamine and Levomilnacipran.	Chronic pain [MG30]	[29]
Selegiline	DM6034S	Major	Additive hypertensive effects by the combination of Dopamine and Selegiline.	Depression [6A70-6A7Z]	[27]
Isocarboxazid	DMAF1NB	Major	Additive hypertensive effects by the combination of Dopamine and Isocarboxazid.	Depression [6A70-6A7Z]	[27]
Milnacipran	DMBFE74	Moderate	Increased risk of rapid heart rate by the combination of Dopamine and Milnacipran.	Depression [6A70-6A7Z]	[29]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of rapid heart rate by the combination of Dopamine and Desvenlafaxine.	Depression [6A70-6A7Z]	[29]
Procarbazine	DMIK367	Major	Increased risk of hyperpyrexia by the combination of Dopamine and Procarbazine.	Hodgkin lymphoma [2B30]	[27]
Ozanimod	DMT6AM2	Major	Additive hypertensive effects by the combination of Dopamine and Ozanimod.	Multiple sclerosis [8A40]	[27]
Sibutramine	DMFJTDI	Moderate	Increased risk of rapid heart rate by the combination of Dopamine and Sibutramine.	Obesity [5B80-5B81]	[30]
Ergonovine	DM0VEC1	Major	Additive hypertensive effects by the combination of Dopamine and Ergonovine.	Postpartum haemorrhage [JA43]	[31]
-----------


⏷ Show the Full List of 11 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Hydrochloric acid	E00015	313	Acidulant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Quinoline yellow WS	E00309	24671	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Dextrose monohydrate	E00538	22814120	Binding agent; Diluent; Flavoring agent; Tonicity agent
Ethanol	E00023	702	Antimicrobial preservative; Penetration agent; Solvent
Magnesium stearate	E00208	11177	lubricant
Sodium citrate dihydrate	E00369	71474	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium metabisulfite	E00444	656671	Antimicrobial preservative; Antioxidant
Water	E00035	962	Solvent
Sodium sulhydrate	E00549	23665763	Antimicrobial preservative
--------------------


⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dopamine 25-100 tablet	25-100	Oral Tablet	Oral
Dopamine Hydrochloride 800 mcg/ml injectable	800 mcg/ml	Injectable	Injection
Dopamine Hydrochloride 40mg/ml injectable	40mg/ml	Injectable	Injection
Dopamine Hydrochloride 6x injectable	6x	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Dopamine FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 940).
3	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Discovery and replication of dopamine-related gene effects on caudate volume in young and elderly populations (N=1198) using genome-wide search. Mol Psychiatry. 2011 Sep;16(9):927-37, 881. doi: 10.1038/mp.2011.32. Epub 2011 Apr 19.
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
9	Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2253-E2262.
10	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
11	Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
12	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
13	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
14	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
15	Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine. Pharmacogenetics. 1998 Jun;8(3):251-8.
16	Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):651-60.
17	Molecular cloning, expression, and functional characterization of novel mouse sulfotransferases. Biochem Biophys Res Commun. 1998 Jun 29;247(3):681-6.
18	Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32.
19	Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445). pii: eaau6323.
20	Mitochondrial proteomics investigation of a cellular model of impaired dopamine homeostasis, an early step in Parkinson's disease pathogenesis. Mol Biosyst. 2014 Jun;10(6):1332-44.
21	G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. Neurochem Int. 2004 Oct;45(5):669-76. doi: 10.1016/j.neuint.2004.03.029.
22	Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine. Toxicol Lett. 2016 Jan 22;243:48-55.
23	Effects of dopamine on LC3-II activation as a marker of autophagy in a neuroblastoma cell model. Neurotoxicology. 2009 Jul;30(4):658-65. doi: 10.1016/j.neuro.2009.04.007. Epub 2009 May 4.
24	Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp Mol Med. 2007 Jun 30;39(3):376-84. doi: 10.1038/emm.2007.42.
25	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
26	Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A "The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine." Clin Pharmacol Ther 58 (1995): 221-7. [PMID: 7648772]
27	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
28	Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
29	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
30	Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
31	Barthel W, Glusa E, Koth W "Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ." Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9. [PMID: 2881898]